Improving outcomes for people of color with chronic plaque psoriasis including scalp involvement
Jointly provided by the Postgraduate Institute for Medicine and Scientific Education Support
CLINICAL TRIAL CLUB
Improving outcomes for people of color with chronic plaque psoriasis including scalp involvement
Join us for an informative webinar that will discuss improving outcomes for people of color with chronic plaque psoriasis including scalp involvement.
The webinar aims to enhance understanding of best practice recommendations for the management of psoriasis in different populations, including people of color. Our expert panel will discuss unmet needs for people of color with psoriatic disease and new guidance for diversity within clinical trials, before providing an overview of the VISIBLE trial (NCT05272150). Additionally, there will be a live Q&A session in which you can speak directly to the panel.
Target Audience
This activity is intended for healthcare professionals engaged in the care of patients with psoriasis.
Agenda
Unmet needs for people of color with psoriatic disease and new guidance for diversity within clinical trials
All, led by Paolo Gisondi
Discussion and Q&A
All, led by Paolo Gisondi
Discussion and Q&A
Learning objectives
Upon completion of this activity, participants should be able to:
- Appraise factors that can affect diagnosis of psoriasis in people of color
- Recall key data from clinical trials for approved and pipeline treatments for psoriasis
- Explain the considerations for optimal, individualized treatment selection
- Describe best practice recommendations for the management of psoriasis in different populations, including people of color
Our speakers
Meet our panel of experts
Paolo Gisondi
University Hospital of Verona
Verona, IT
Andrew Alexis
Weill Cornell Medicine
New York, US
Mona Shahriari
Yale University School of Medicine
Connecticut, US
Accreditation information
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Scientific Education Support. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0MA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Disclosure of financial relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this activity:
Paolo Gisondi: Speakers Bureau/Honoraria for non-CME: Amgen Abbvie Almirall UCB, Jannsen, Eli Lilly; Consultant/Advisory Board: Amgen Abbvie Almirall UCB, Jannsen, Eli Lilly
Andrew Alexis: Grant/Research Support: Leo, Amgen, Galderma, Arcutis, Dermavant, Abbvie, Castle, Incyte; Speakers Bureau/Honoraria for non-CME: Regeneron, SANOFI-Genzyme, BMS, L'Oreal, Janssen, J&J, Aerolase; Consultant/Advisory Board: Leo, Galderma, Pfizer, Sanofi-Regeneron, Genzyme, Dermavant, Beiersdorf, Ortho, L’Oreal, BMS, Bausch health , UCB, Arcutis, Janssen, Allergan, Almirall, Abbvie, Amgen, VisualDx, Eli Lilly, Swiss American, Cutera, Cara, EPI, Incyte, Castle, Apogee, Canfield, Alphyn, Avita Medical, Genentech, Boehringer Ingelheim, Symrise; Patent Holder/Royalties paid to you: Springer, Wiley-Blackwell, Wolters Kluwer Health, Elsevier; Other financial or material support: Equipment loan to institution- Aerolase.
Mona Shahriari: Grant/Research Support: AbbVie, CorEvitas Psoriasis and Atopic Dermatitis Registry, Dermira, Cara, Dermavant, Novartis, Union, Mindera; Speakers Bureau/Honoraria for non-CME: Abbvie, Arcutis, Bristol Myers Squibb, Lilly USA, Janssen, Dermavant, Pfizer, Galderma, UCB, Sanofi, Regeneron; Consultant/Advisory Board: AbbVie, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Pfizer, Incyte, Janssen, Leo Pharma, Lilly USA, Novartis, Sanofi-Genzyme, Regeneron, UCB
The PIM planners and others have nothing to disclose.
About SES
Delivering streamlined independent medical education to enhance clinical practice. SES hubs allow time-stretched healthcare professionals to easily access curated scientific, medical, and clinical information that expedites their learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, our hubs support healthcare professionals worldwide with up-to-date, accessible, and impactful educational content.
About the PsOPsA Hub
The PsOPsA Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in psoriasis and psoriatic arthritis. Our aim is to enhance knowledge on psoriasis and psoriatic arthritis, through the multichannel dissemination of global advances related to classification, diagnosis, treatment, and management.
The PsOPsA Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.